Repeated localized treatment for extranodal marginal zone lymphoma - Case report and review of literature

Christine E. Schönknecht; Carsten Nieder; Michael Molls; Sabrina T. Astner

Repeated localized treatment for extranodal marginal zone lymphoma - Case report and review of literature

Christine E. Schönknecht
, Carsten Nieder
, Michael Molls
, Sabrina T. Astner

TUM Institute for Advanced Study

Technical University of Munich
Nordland Hospital
UIT The Arctic University of Norway

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: Marginal zone lymphomas (MZL) are indolent B-cell lymphomas with variable symptoms related to lymphoma location. Patients with such lymphoma often have an excellent prognosis. Concerning treatment, no large prospective trials have been published, making therapeutic decisions difficult. Case Report: The Authors present the case of a female patient with an MZL which was slowly progressive throughout 9 years after diagnosis. Only clearly progressive lymphoma manifestations were treated with moderate-dose radiotherapy (total doses between 30 and 40 Gy). All irradiated lesions showed a complete regression and relapses only occurred at non-irradiated sites. The performance status remains very good. Conclusion: Moderate-dose radiotherapy is a safe and effective treatment to achieve local tumor control in patients with MZL.

Original language	English
Pages (from-to)	3935-3938
Number of pages	4
Journal	Anticancer Research
Volume	31
Issue number	11
State	Published - Nov 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

B-cell lymphoma
Local tumor control
Marginal zone lymphoma
Radiation therapy

Cite this

@article{5e7d89311489420286c3ac2e84fda833,

title = "Repeated localized treatment for extranodal marginal zone lymphoma - Case report and review of literature",

abstract = "Background: Marginal zone lymphomas (MZL) are indolent B-cell lymphomas with variable symptoms related to lymphoma location. Patients with such lymphoma often have an excellent prognosis. Concerning treatment, no large prospective trials have been published, making therapeutic decisions difficult. Case Report: The Authors present the case of a female patient with an MZL which was slowly progressive throughout 9 years after diagnosis. Only clearly progressive lymphoma manifestations were treated with moderate-dose radiotherapy (total doses between 30 and 40 Gy). All irradiated lesions showed a complete regression and relapses only occurred at non-irradiated sites. The performance status remains very good. Conclusion: Moderate-dose radiotherapy is a safe and effective treatment to achieve local tumor control in patients with MZL.",

keywords = "B-cell lymphoma, Local tumor control, Marginal zone lymphoma, Radiation therapy",

author = "Sch{\"o}nknecht, \{Christine E.\} and Carsten Nieder and Michael Molls and Astner, \{Sabrina T.\}",

year = "2011",

month = nov,

language = "English",

volume = "31",

pages = "3935--3938",

journal = "Anticancer Research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "11",

}

TY - JOUR

T1 - Repeated localized treatment for extranodal marginal zone lymphoma - Case report and review of literature

AU - Schönknecht, Christine E.

AU - Nieder, Carsten

AU - Molls, Michael

AU - Astner, Sabrina T.

PY - 2011/11

Y1 - 2011/11

N2 - Background: Marginal zone lymphomas (MZL) are indolent B-cell lymphomas with variable symptoms related to lymphoma location. Patients with such lymphoma often have an excellent prognosis. Concerning treatment, no large prospective trials have been published, making therapeutic decisions difficult. Case Report: The Authors present the case of a female patient with an MZL which was slowly progressive throughout 9 years after diagnosis. Only clearly progressive lymphoma manifestations were treated with moderate-dose radiotherapy (total doses between 30 and 40 Gy). All irradiated lesions showed a complete regression and relapses only occurred at non-irradiated sites. The performance status remains very good. Conclusion: Moderate-dose radiotherapy is a safe and effective treatment to achieve local tumor control in patients with MZL.

AB - Background: Marginal zone lymphomas (MZL) are indolent B-cell lymphomas with variable symptoms related to lymphoma location. Patients with such lymphoma often have an excellent prognosis. Concerning treatment, no large prospective trials have been published, making therapeutic decisions difficult. Case Report: The Authors present the case of a female patient with an MZL which was slowly progressive throughout 9 years after diagnosis. Only clearly progressive lymphoma manifestations were treated with moderate-dose radiotherapy (total doses between 30 and 40 Gy). All irradiated lesions showed a complete regression and relapses only occurred at non-irradiated sites. The performance status remains very good. Conclusion: Moderate-dose radiotherapy is a safe and effective treatment to achieve local tumor control in patients with MZL.

KW - B-cell lymphoma

KW - Local tumor control

KW - Marginal zone lymphoma

KW - Radiation therapy

UR - https://www.scopus.com/pages/publications/83055162494

M3 - Article

C2 - 22110222

AN - SCOPUS:83055162494

SN - 0250-7005

VL - 31

SP - 3935

EP - 3938

JO - Anticancer Research

JF - Anticancer Research

IS - 11

ER -

Repeated localized treatment for extranodal marginal zone lymphoma - Case report and review of literature

Abstract

UN SDGs

Keywords

Other files and links

Fingerprint

Cite this